KBI Biopharma Names JB Agnus as Chief Business Officer

KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has appointed Jean-Baptiste (JB) Agnus as its Chief Business Officer.
 
Agnus brings more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and the latest advancements in cell and gene therapies. Agnus will lead KBI’s global business development initiatives to drive the company toward continued growth and sustained success. This role is focused on building and maintaining long-lasting partnerships with KBI’s current and future customers around the globe.
 
Before joining KBI, Agnus held leadership roles in business development at AGC Biologics, Ajinomoto Bio-Pharma Services, Novasep, and Isochem. He holds a Master of Science in Chemical Engineering from Centrale Marseille.
 
“Our dedication to growth and commitment to our partners, their patients, and our people guide every decision at KBI Biopharma,” remarked J.D. Mowery, President & CEO of KBI Biopharma. “JB’s appointment underscores this dedication, perfectly aligning with our team’s mission to deliver innovative, top-tier solutions tailored to our customers’ evolving needs. His servant leadership philosophy will further fortify our team, propelling KBI to new heights.”
 
“KBI Biopharma is an innovator in the testing, development, manufacturing, and commercialization of life-changing therapies,” said Agnus. “Strong partnerships are at the core of KBI’s success. I am excited to join the passionate team at KBI, who are committed to ensuring transformative treatments reach those in need by nurturing meaningful customer relationships.”